ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2670

Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle

Cecilia Leijding1, Suchada Kaewin2, Kristofer Andreasson1, Tomas Schiffer1, Angeles Galindo-Feria3, Begum Horuluoglu1, Mattias Carlstrom1, Stefano Gastaldello1, Helene Alexanderson4, Ingrid Lundberg5 and Daniel Andersson6, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, 3Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Karolinska University Hospital, Stockholm, Sweden, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 6Karolinska Institutet, Solna, Sweden

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Mitochondrial Dysfunction, Muscle Biology, Muscle Function, Myopathies, Myositis

Session Information

Date: Tuesday, November 19, 2024

Title: Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs of inflammatory cell infiltrates in the muscles are commonly seen, correlation lacks between the degree of infiltrates and muscle weakness or fatigue. The mechanisms causing the muscle weakness in IIM remain unclear. Considering the systemic inflammation involved in IIM, our hypothesis proposes that blood-borne factors contribute to muscle dysfunction by affecting the contractile apparatus within muscle fibers.

Methods: Isolated whole flexor digitorum brevis (FDB) muscles from female mice (C57BL/6JRj) were incubated for 24h in DMEM buffer containing either 10% or 50% of serum from patients with IIM (n=5) or from healthy controls (n=2) (Fig 1B-E). Muscle force-frequency measurements were assessed before and after incubation of the muscles via electrical stimulations at increasing frequencies (15-100Hz). Interferon-1 (IFN1) and myositis autoantibodies (e.g. FHL1) have been implied in the pathogenesis of IIM. In some expreriments we incubated muscles with IFN1 (Fig1F) or total IgG from seropositive IIM patients (Fig 1G). Mitochondrial respiration in permeabilized muscles was assessed with high-resolution respirometry (Oroboros). qPCR was used to measure gene expression in incubated muscles.

Results: In whole muscles exposed to sera from patients with IIM, we found a significantly reduced force generation in a serum-dose dependent manner that was not observed after incubation in healthy control sera (Fig 1B-E; p< 0.05). Incubation with IFN1 or IIM patient IgG did not affect muscle force (Fig1F-G). The activity of mitochondrial respiratory chain (complex I-III) was reduced (Fig 1H; P< 0.05), and mitochondrial biogenesis regulatory genes (PGC1α, NRF1/2; P< 0.05) displayed lower expression (Fig 1I) after incubation with IIM sera when compared to healthy sera, indicating metabolic stress. IIM serum incubation induced the gene expression for some inflammatory cytokines (IL1b & TNF; P< 0.05), suggesting that local cytokine production within the muscle fibers (Fig 1J).

Conclusion: Sera from patients with IIM can initiate a phenotype of inflammatory activation, muscle weakness and metabolic dysfunction in an intact isolated healthy skeletal muscle preparation. By using isolated mouse muscle preparations in sera from human patients with IIM, we have developed an experimental platform to study mechanisms that could contribute to muscle weakness in patients with IIM.

Supporting image 1

Figure 1. A, Experimental platform. B-E, Force-frequency curves from FDB muscles before and after exposure to 10% or 50% sera from patients with Idiopathic inflammatory myopathies (IIM) (red) and healthy controls (CON) (blue). F-G, Force-frequency curves from FDB muscles before-after exposure to interferon type 1 (F; IFN1; 50pg/ml) or purified total IgG (150µg/ml) from 3 patients with seropositiv myositis including the anti-FHL1 that targets muscle proteins (G). H, Mitochondrial respiratory chain function (complex I-III) in FDB muscles after exposure to sera from IIM patients (red/pink) or CON (blue). I-J, Gene expression in FDB muscles after exposure to sera, fold change in IIM serum exposed muscles compared to control (blue dotted line). Graphics (A) created with BioRender.com.


Disclosures: C. Leijding: None; S. Kaewin: None; K. Andreasson: None; T. Schiffer: None; A. Galindo-Feria: None; B. Horuluoglu: None; M. Carlstrom: None; S. Gastaldello: None; H. Alexanderson: None; I. Lundberg: Argenx, 1, Astra Zeneca, 1, Boehringer Ingelheim, 6, Bristol Myers Squibb, 1, Chugai, 1, Galapagos, 1, Janssen, 1, 6, Novartis, 11, Pfizer, 1, Roche, 11; D. Andersson: None.

To cite this abstract in AMA style:

Leijding C, Kaewin S, Andreasson K, Schiffer T, Galindo-Feria A, Horuluoglu B, Carlstrom M, Gastaldello S, Alexanderson H, Lundberg I, Andersson D. Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/sera-from-patients-with-idiopathic-inflammatory-myopathy-induces-muscle-weakness-mitochondrial-dysfunction-and-induction-of-cytokines-in-isolated-skeletal-muscle/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sera-from-patients-with-idiopathic-inflammatory-myopathy-induces-muscle-weakness-mitochondrial-dysfunction-and-induction-of-cytokines-in-isolated-skeletal-muscle/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology